• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?

作者信息

Garattini Livio, Curto Alessandro

机构信息

CESAV, Centre for Health Economics, IRCCS Institute for Pharmacological Research 'Mario Negri', Via Camozzi, 3 c/o Villa Camozzi, Ranica, 24020, Bergamo, Italy.

出版信息

Pharmacoeconomics. 2016 Oct;34(10):967-9. doi: 10.1007/s40273-016-0420-1.

DOI:10.1007/s40273-016-0420-1
PMID:27260615
Abstract
摘要

相似文献

1
Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?意大利基于绩效的协议：“时髦的成果”还是纯粹的幻想？
Pharmacoeconomics. 2016 Oct;34(10):967-9. doi: 10.1007/s40273-016-0420-1.
2
Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.意大利当前基于绩效的方案真的有效吗？“成功费”：一种控制药品支出成本的新措施。
Value Health. 2015 Jan;18(1):131-6. doi: 10.1016/j.jval.2014.09.007. Epub 2014 Nov 11.
3
Reimbursement systems and quality of hospital care: an empirical analysis for Italy.报销制度与医院服务质量：以意大利为例的实证分析。
Health Policy. 2013 Aug;111(3):273-89. doi: 10.1016/j.healthpol.2013.05.014. Epub 2013 Jul 2.
4
Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.意大利目前基于绩效的方案真的有效吗？“成功费”：一种控制药品支出成本的新措施。
Value Health. 2015 Mar;18(2):352. doi: 10.1016/j.jval.2014.12.003. Epub 2015 Jan 22.
5
[Pay for performance in primary care].[基层医疗中的绩效薪酬]
Ig Sanita Pubbl. 2011 Sep-Oct;67(5):531-40.
6
The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate.基于结果的市场准入协议中替代终点和患者相关终点的使用：当前辩论
Appl Health Econ Health Policy. 2017 Feb;15(1):5-11. doi: 10.1007/s40258-016-0274-x.
7
[Innovative agreements with the pharmaceutical industry: "pay for performance"].与制药行业的创新协议：“按绩效付费”
Farm Hosp. 2010 Mar-Apr;34(2):53-5. doi: 10.1016/j.farma.2009.12.004. Epub 2010 Mar 6.
8
Reducing the price of new hepatitis C drugs in the Tuscany region of Italy.降低意大利托斯卡纳地区新型丙型肝炎药物的价格。
BMJ. 2015 Jun 24;350:h3363. doi: 10.1136/bmj.h3363.
9
Pay-for-performance in health care: what can we learn from international experience?医疗保健领域的绩效薪酬：我们能从国际经验中学到什么？
Qual Manag Health Care. 2013 Jan-Mar;22(1):2-15. doi: 10.1097/QMH.0b013e31827dea50.
10
Where are we on "risk-sharing" agreements?我们在“风险分担”协议方面进展如何？
Value Health. 2013 Jul-Aug;16(5):701-2. doi: 10.1016/j.jval.2013.04.012. Epub 2013 Jun 14.

引用本文的文献

1
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.管理准入协议对药品供应和及时获取的影响：在四个国家实施的肿瘤治疗协议的事后评估。
BMC Health Serv Res. 2022 Aug 20;22(1):1066. doi: 10.1186/s12913-022-08437-w.
2
How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements.风险分担协议的风险有多大？六种常见风险分担协议的均值-方差权衡与意外后果。
MDM Policy Pract. 2021 Feb 9;6(1):2381468321990404. doi: 10.1177/2381468321990404. eCollection 2021 Jan-Jun.
3

本文引用的文献

1
'Appropriateness' in Italy: A 'Magic Word' in Pharmaceuticals?
Appl Health Econ Health Policy. 2017 Feb;15(1):1-3. doi: 10.1007/s40258-016-0240-7.
2
Authors' Reply to Palozzo and Messori: ''Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review''.
Pharmacoeconomics. 2016 Apr;34(4):421-2. doi: 10.1007/s40273-016-0383-2.
3
MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.意大利药品管理局的监测登记系统：促进获取，保障可持续性。
Int J Technol Assess Health Care. 2015 Jan;31(4):210-3. doi: 10.1017/S0266462315000446.
4
Integrative Review of Managed Entry Agreements: Chances and Limitations.
综合管理准入协议审查：机遇与限制。
Pharmacoeconomics. 2020 Nov;38(11):1165-1185. doi: 10.1007/s40273-020-00943-1.
4
Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.欧洲合理用药当前障碍映射（CORUM）：现状与潜在解决方案
Front Pharmacol. 2020 Mar 3;11:144. doi: 10.3389/fphar.2020.00144. eCollection 2020.
5
Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?欧洲的药品支出控制：是时候从定价转向预算了吗？
J R Soc Med. 2020 Mar;113(3):93-97. doi: 10.1177/0141076819894681. Epub 2019 Dec 20.
6
Comparison of United States and International Ophthalmic Drug Pricing.美国与国际眼科药物定价比较。
Ophthalmology. 2019 Oct;126(10):1358-1365. doi: 10.1016/j.ophtha.2019.04.018. Epub 2019 May 27.
7
Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing.欧洲药品平均价格的演变：对外部价格参考方法的影响
Pharmacoecon Open. 2019 Sep;3(3):303-309. doi: 10.1007/s41669-019-0120-9.
8
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?多适应症定价：理论上可行，但实际中能奏效吗？
Pharmacoeconomics. 2018 Dec;36(12):1407-1420. doi: 10.1007/s40273-018-0716-4.
9
Pharmaceutical pricing conundrum: time to get rid of it?药品定价难题：是时候解决它了吗？
Eur J Health Econ. 2018 Nov;19(8):1035-1038. doi: 10.1007/s10198-018-0995-x.
10
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.适应性路径：付款人在为潜在实施做准备时可能采取的后续步骤。
Front Pharmacol. 2017 Aug 23;8:497. doi: 10.3389/fphar.2017.00497. eCollection 2017.
Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.意大利当前基于绩效的方案真的有效吗？“成功费”：一种控制药品支出成本的新措施。
Value Health. 2015 Jan;18(1):131-6. doi: 10.1016/j.jval.2014.09.007. Epub 2014 Nov 11.
5
Market-access agreements for anti-cancer drugs.抗癌药物的市场准入协议。
J R Soc Med. 2015 May;108(5):166-70. doi: 10.1177/0141076814559626. Epub 2014 Dec 8.
6
Italian risk-sharing agreements on drugs: are they worthwhile?意大利药品风险分担协议：它们值得吗？
Eur J Health Econ. 2015 Jan;16(1):1-3. doi: 10.1007/s10198-014-0585-5.
7
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.药品风险分担安排：对欧洲支付方的潜在考虑和建议。
BMC Health Serv Res. 2010 Jun 7;10:153. doi: 10.1186/1472-6963-10-153.
8
Multiple sclerosis risk sharing scheme: a costly failure.多发性硬化症风险分担计划：代价高昂的失败。
BMJ. 2010 Jun 3;340:c1672. doi: 10.1136/bmj.c1672.
9
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.无法获得满足感？付费绩效能否有所帮助？：理解创新型医疗产品基于绩效的风险分担协议的经济框架。
Pharmacoeconomics. 2010;28(2):93-102. doi: 10.2165/11314080-000000000-00000.
10
The pharmaceutical industry--prices and progress.制药行业——价格与进展。
N Engl J Med. 2004 Aug 26;351(9):927-32. doi: 10.1056/NEJMhpr040117.